NeuroKaire Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 41

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $10M

  • Investors
  • 12

NeuroKaire General Information

Description

Operator of a medical platform intended to transform brain health and eliminate suffering precision medicine in psychiatry and neurology. The company's innovative technology also provides pharmaceutical companies with essential tools for targeted drug discovery and development, enabling clinicians to identify the optimal antidepressant based on the response of a patient's brain cells combined with their genetics and medical history.

Contact Information

Website
www.neurokaire.com
Formerly Known As
Genetika Rx, Genetika+
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 78 John Miller Way
  • Kearny, NJ 07032
  • United States
+1 (201)
Primary Industry
Other Healthcare Services
Other Industries
Other Pharmaceuticals and Biotechnology
Diagnostic Equipment
Vertical(s)
LOHAS & Wellness, Digital Health, Artificial Intelligence & Machine Learning, Life Sciences
Corporate Office
  • 78 John Miller Way
  • Kearny, NJ 07032
  • United States
+1 (201)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroKaire Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series A1) 17-May-2024 $10M Completed Generating Revenue
8. Grant 26-Jul-2022 Completed Generating Revenue
7. Early Stage VC (Series A) 01-Nov-2021 Completed Generating Revenue
6. Grant 30-Dec-2020 Completed Generating Revenue
5. Grant 01-Jul-2020 Completed Generating Revenue
4. Seed Round 06-Oct-2019 Completed Generating Revenue
3. Grant 01-Mar-2019 Completed Generating Revenue
2. Accelerator/Incubator 06-Nov-2018 $39.5K $39.5K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view NeuroKaire’s complete valuation and funding history, request access »

NeuroKaire Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preferred A
Preferred Seed-2
Preferred Seed-1 54,769 $7.3 $7.3 1x $7.3 2.27%
To view NeuroKaire’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

NeuroKaire Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a medical platform intended to transform brain health and eliminate suffering precision medicine in psychiat
Other Healthcare Services
Kearny, NJ
41 As of 2026

King of Prussia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeuroKaire Competitors (1)

One of NeuroKaire’s competitors is Genomind, a Venture Capital-Backed company based in King of Prussia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genomind Venture Capital-Backed King of Prussia, PA
You’re viewing 1 of 1 competitors. Get the full list »

NeuroKaire Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

NeuroKaire Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3168020-A1 Methods of therapeutic prognostication Pending 16-Feb-2020
EP-4103045-A1 Methods of therapeutic prognostication Pending 16-Feb-2020
EP-4103045-A4 Methods of therapeutic prognostication Pending 16-Feb-2020
US-12775004-B2 Methods of therapeutic prognostication Active 16-Feb-2020
US-20230094922-A1 Methods of therapeutic prognostication Active 16-Feb-2020 G01N33/5058
To view NeuroKaire’s complete patent history, request access »

NeuroKaire Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroKaire Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Innovation Council Accelerator/Incubator Minority
GreyBird Ventures Venture Capital Minority
Hilltop Venture Partners Venture Capital Minority
Angel (individual) Minority
Calcalist Corporation
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

NeuroKaire FAQs

  • When was NeuroKaire founded?

    NeuroKaire was founded in 2018.

  • Where is NeuroKaire headquartered?

    NeuroKaire is headquartered in Kearny, NJ.

  • What is the size of NeuroKaire?

    NeuroKaire has 41 total employees.

  • What industry is NeuroKaire in?

    NeuroKaire’s primary industry is Other Healthcare Services.

  • Is NeuroKaire a private or public company?

    NeuroKaire is a Private company.

  • What is NeuroKaire’s current revenue?

    The current revenue for NeuroKaire is .

  • How much funding has NeuroKaire raised over time?

    NeuroKaire has raised $21.2M.

  • Who are NeuroKaire’s investors?

    European Innovation Council, GreyBird Ventures, Hilltop Venture Partners, , and Calcalist are 5 of 12 investors who have invested in NeuroKaire.

  • Who are NeuroKaire’s competitors?

    Genomind is a competitor of NeuroKaire.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process